Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Drug Induced Liver Disease
How would you approach the management of drug-induced autoimmune hepatitis compared to non-drug-induced autoimmune hepatitis?
Related Questions
When do you pursue liver biopsy for assessment of DILI?
How do you counsel patients on the use and risks of alternative medications and supplements given how prevalent and easily accessible they are to the average person?
What kind of follow up or monitoring do you recommend for patients with at risk alpha-1-anti-trypsin phenotypes?
What are your clinical considerations to pursue an automated-low-flow ascites (ALFA) pump for a patient with refractory ascites?
How would you differentiate neurologic manifestations of a patient with Wilson's disease versus manifestations of hepatic encephalopathy due to end-stage liver disease?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
For how long would you treat a patient with latent TB before allowing them to proceed with a liver transplant?
What patient factors guide your selection of maintenance therapies for a patient with auto-immune hepatitis?
How do you approach the evaluation of a living donor liver transplant candidate? What kind of patient would be an ideal recipient of such an organ?
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
